Jobs / United States / Astrazeneca Pharmaceuticals Lp
Global Commercial Head, GI ADC
Astrazeneca Pharmaceuticals Lp · 🇺🇸 US - Gaithersburg - MD
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles1 certified filing for “Global Product Teams Finance Director, R&D Finance” (Financial Managers) in MD: $196k–$196k, median $196k. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Astrazeneca Pharmaceuticals Lp
The US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Astrazeneca Pharmaceuticals Lp →
About the role
AstraZeneca is at an amazing trajectory, rapidly and successfully emerging into a key leader in Oncology. Together we deliver transformational medicines across a broad range of major indications, making a significant difference for patients worldwide every day. Focusing on the potential of science to address unmet need, we are specifically committed to those areas where we can really change the course of medicine and bring big new ideas to life. As Commercial Leadership within Oncology, our ability to effectively and creatively market our products and lead our business has a meaningful impact. It powers our business to lead the way for the industry and to impact more lives – making a difference to those living with cancer. Working across our broad and innovative pipeline, we fuse our business mentality and scientific knowledge to bring transformative medicines and novel treatments to those who need it the most. True team players, we’re a place of trust, excellence and opportunity – where everyone is encouraged to add challenge and excitement to the everyday. Here we try new things, take calculated risks and work as one to go further, faster. Together, as daring experts, we’re building the future and leading the next wave of transformation for our patients, business and Oncology. As the Global Commercial Head, GI ADC, you’ll play a pivotal role in making a positive impact on changing patients’ lives building a new franchise to change the paradigm of care for patients with gastric cancers and other GI tumors. This role is a key contributor to future growth, across OBU and specifically for our GI Cancer portfolio, we seek dedicated global commercial leadership to launch and enhance the global potential of the brand and seek new opportunities with our R&D colleagues. The Global Commercial Head, GI ADC , will be accountable for commercial leadership and brand strategy across several indications in early and metastatic gastric cancer including launch readiness, growth and life cycle strategies with new investments across the GI cancer landscape. You will be responsible and accountable for the development and implementation of the brand strategic plan in multiple GI cancer indications including market development, as well as engaging with regions and key markets to drive launch readiness and commercial excellence. You will grow and develop the Sone-Ve global marketing team for current and future in Gastric Cancer and, as appropriate, in other tumor types, as well as provide matrix leadership to colleagues in Medical Affairs, Business Insights, Pricing, Market Access, Diagnostics and Communications. Who you are: You are a hard-working leader who is excited about the opportunity to create trust, credibility and value in the long run, in one of the most dynamic and rapidly expanding scientific and commercial areas in healthcare: Oncology. You can think globally and locally. You can integrate a variety of perspectives into meaningful strategies and programs. You embrace curiosity, collaboration and hard-working risk taking as a prerequisite for joint success. You speak up and challenge, always towards better outcomes and towards highest integrity. You enthusiastically embrace the diversity of individual healthcare ecosystems as significant opportunity. You can relate and connect deeply with various healthcare and business markets in order to deliver direction and support. You can create and mobilize a work environment of highest integrity and quality, fostering learning, growth, individual development and attraction of top talent. Accountabilities: • Accountable for commercial strategy, go to market commercialization and growth strategies for Sone-Ve in multiple gastric cancer indications (as well as potential in other GI cancers) •